Edition:
United States

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

20.00USD
2:15pm EDT
Change (% chg)

$0.20 (+1.01%)
Prev Close
$19.80
Open
$20.05
Day's High
$20.05
Day's Low
$19.95
Volume
11,933
Avg. Vol
167,226
52-wk High
$39.95
52-wk Low
$16.75

Latest Key Developments (Source: Significant Developments)

Lannett announces FDA approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml
Tuesday, 16 May 2017 06:52am EDT 

May 16 (Reuters) - Lannett Company Inc :Lannett announces approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml (0.5 mg/ml).Lannett says levocetirizine dihydrochloride oral solution will be manufactured in Carmel, New York by Silarx Pharmaceuticals.  Full Article

Lannett Company Inc files for potential mixed shelf size not disclosed
Friday, 12 May 2017 05:14pm EDT 

May 12 (Reuters) - Lannett Company Inc ::Lannett Company Inc files for potential mixed shelf; size not disclosed - sec filing.  Full Article

Lannett voluntarily pays down remaining $25 mln principal balance of revolving credit facility
Tuesday, 9 May 2017 06:53am EDT 

May 9 (Reuters) - Lannett Company Inc :Lannett voluntarily pays down remaining $25 million principal balance of revolving credit facility.Will save approximately $7.3 million in annualized cash interest expense, at current rates as result of paying down balance of facility.  Full Article

Lannett reports Q3 earnings per share $0.40
Tuesday, 2 May 2017 04:15pm EDT 

May 2 (Reuters) - Lannett Company Inc :Lannett reports fiscal 2017 third-quarter financial results.Q3 adjusted earnings per share $0.77.Q3 earnings per share $0.40.Q3 sales $165.7 million versus I/B/E/S view $170.5 million.Q3 earnings per share view $0.87 -- Thomson Reuters I/B/E/S.Lannett Company Inc says company expects its fiscal 2017 Q4 profitability on an adjusted basis to be similar with its fiscal 2017 Q3.  Full Article

Lannett voluntarily pays down additional $25 mln of revolving credit facility
Thursday, 30 Mar 2017 06:53am EDT 

Lannett Company Inc : Lannett voluntarily pays down additional $25 million of revolving credit facility .Lannett Co - $25 million payment, combined with $75 million payment made earlier in Jan, to save co about $5.5 million in annualized cash interest expense at current rates.  Full Article

Lannett Co says FDA agreed to delay submission deadline for Methylphenidate ER tablets
Wednesday, 22 Feb 2017 06:54am EST 

Lannett Company Inc : Lannett provides further update on methylphenidate er tablets . Lannett company inc- FDA agreed to delay submission deadline for Methylphenidate ER tablets . Lannett company-FDA suspended deadline to submit materials in support of its request for hearing to consider FDA's proposal co withdraw ANDA for Methylphenidate ER . Lannett co-FDA expected to discuss sufficiency of documents related to Methylphenidate ER tablets with co once documents are released .Lannett co-FDA expected to establish new dates for submission of materials in support of hearing request.  Full Article

Lannett's subsidiary to launch $50 mln expansion - SEC filing
Tuesday, 31 Jan 2017 08:51am EST 

Lannett Company Inc :Lannett Company Inc - Cody Laboratories, a wholly owned subsidiary of company, would be launching a $50 million expansion to its facilities - SEC filing.  Full Article

Lannett announces approval for memantine hydrochloride tablets USP, 5 mg and 10 mg
Monday, 14 Nov 2016 06:56am EST 

Lannett Company Inc : Lannett announces approval for memantine hydrochloride tablets usp, 5 mg and 10 mg .Lannett company inc - "expect to commence marketing product in approximately two months".  Full Article

Lannett reports fiscal 2017 Q1 financial results
Thursday, 3 Nov 2016 04:15pm EDT 

Lannett Company Inc : Lannett Company Inc - Revises guidance for fiscal 2017 . Lannett Company Inc sees 2017 GAAP net sales $675 million to $685 million; down from $690 million to $700 million . Lannett Company Inc sees 2017 non-GAAP net sales $675 million to $685 million; down from $690 million to $700 million . Lannett Company Inc sees 2017 GAAP gross margin in range of 51.5% to 52.5%, up from 50% to 51% . Lannett Company Inc sees 2017 adjusted gross margin between 57.5% to 58.5%; up from 55% to 56% . FY2017 revenue view $683.1 million -- Thomson Reuters I/B/E/S . Lannett reports fiscal 2017 first-quarter financial results . Q1 adjusted earnings per share $0.77 . Q1 loss per share $0.80 . Q1 sales $162 million versus I/B/E/S view $166.7 million .Q1 earnings per share view $0.71 -- Thomson Reuters I/B/E/S.  Full Article

Lannett Q4 adjusted earnings per share $0.73
Tuesday, 23 Aug 2016 04:15pm EDT 

Lannett Company Inc : Lannett announces record net sales for fiscal 2016 fourth-quarter and full-year . Q4 adjusted earnings per share $0.73 . Q4 earnings per share $0.10 . Q4 sales $168.9 million versus i/b/e/s view $161.6 million . Q4 earnings per share view $0.59 -- Thomson Reuters I/B/E/S . Lannett Company Inc Sees fiscal 2017 capital expenditures $55 million to $65 million . Lannett Company Inc sees FY 2017 net sales to be between $690 million and $700 million . Lannett company inc sees fiscal 2017 gaap gross margin percentage 50% to 51% .Lannett Company Inc sees fiscal 2017 adjusted gross margin percentage 55% to 56%.  Full Article

More From Around the Web

BRIEF-Lannett announces FDA approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml

* Lannett announces approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml (0.5 mg/ml)